Skip to content
Screener

Bicara Therapeutics BCAX Business Segments — Interest Income

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — Interest Income
$2.5M+400%
nCino, Inc. logo
NCNOReportable Segment — Interest Income
$366K-12.2%
DocuSign logo
DOCUReportable Segment — Interest Income
$8.73M-18.4%
UiPath logo
PATHReportable Segment — Interest Income
$10.4M-17.8%
YSS
YSSReportable Segment — Interest Income
$4.62M+754%
Intuitive Machines, Inc. logo
LUNRReportable Segment — Interest Income
$1.43M+0.8%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.81B+217%
Enterprise value$1.49B+1,000%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033429
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Total general and administrative expenses12,7427,455
Total operating expenses60,24241,788
Operating loss(60,242)(41,788)
Interest income4,0835,014
Total other income4,0835,014
Net income before losses(56,159)(36,774)
Income tax expense(52)(72)
Segment and consolidated net loss$(56,211)$(36,846)

Item 1. Financial Statements (Unaudited)

FAQ

What is Bicara Therapeutics's business segments — interest income?
Bicara Therapeutics (BCAX) reported business segments — interest income of $4.08M in Q1 2026.
How has Bicara Therapeutics's business segments — interest income changed year-over-year?
Bicara Therapeutics's business segments — interest income decreased by 18.6% year-over-year, from $5.01M to $4.08M.
What is the long-term trend for Bicara Therapeutics's business segments — interest income?
Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — interest income has grown at a 268.8% compound annual growth rate (CAGR), from $1.31M to $17.87M.
What does business segments — interest income mean?
This metric reflects the revenue earned from cash, cash equivalents, and marketable securities held by the company. For a clinical-stage biopharmaceutical firm, this represents the return on capital raised to fund ongoing research and development programs.

Ask your AI about Bicara Therapeutics's business segments — interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude